方盛制药
(603998)
| 流通市值：51.20亿 | | | 总市值：51.20亿 |
| 流通股本：4.39亿 | | | 总股本：4.39亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,253,315,302.11 | 834,248,975.63 | 418,083,503.37 | 1,777,494,393.87 |
| 营业收入 | 1,253,315,302.11 | 834,248,975.63 | 418,083,503.37 | 1,777,494,393.87 |
| 二、营业总成本 | 1,022,150,726.68 | 683,068,914.91 | 340,146,773.39 | 1,531,784,897.55 |
| 营业成本 | 360,009,924.99 | 247,790,990.68 | 123,326,150.06 | 500,368,336.15 |
| 税金及附加 | 24,810,444.67 | 16,069,167.7 | 8,073,005.35 | 30,981,768.79 |
| 销售费用 | 420,256,241.42 | 280,128,148.16 | 141,018,818.65 | 702,914,018.48 |
| 管理费用 | 100,205,310.56 | 64,926,056.81 | 32,547,234.78 | 145,849,448.13 |
| 研发费用 | 108,080,333.17 | 68,088,518.71 | 31,879,608.54 | 139,214,230.43 |
| 财务费用 | 8,788,471.87 | 6,066,032.85 | 3,301,956.01 | 12,457,095.57 |
| 其中:利息费用 | 11,683,354.73 | 8,158,700.25 | 4,467,680.52 | 21,785,269.86 |
| 其中:利息收入 | 3,212,328.53 | 2,285,280.76 | 1,282,843.79 | 9,660,242.2 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | - | -21,182.07 |
| 加:投资收益 | 2,241,754.08 | 1,376,986.92 | -812,038.81 | 38,557,369.89 |
| 资产处置收益 | 51,397,589.85 | 20,660,730.85 | 15,272,816.18 | 746,351.63 |
| 资产减值损失(新) | -73,274.91 | -54,625.6 | 376,880.9 | -20,619,446.54 |
| 信用减值损失(新) | 3,383,200.91 | 4,220,282.52 | 2,864,893.35 | -5,184,775.58 |
| 其他收益 | 11,714,915.47 | 9,729,191.43 | 3,665,909.9 | 26,156,471.26 |
| 四、营业利润 | 299,828,760.83 | 187,112,626.84 | 99,305,191.5 | 285,344,284.91 |
| 加:营业外收入 | 468,594.16 | 147,055.43 | 85,474.56 | 1,278,749.98 |
| 减:营业外支出 | 1,134,858.07 | 766,371.56 | 222,345.92 | 635,493.2 |
| 五、利润总额 | 299,162,496.92 | 186,493,310.71 | 99,168,320.14 | 285,987,541.69 |
| 减:所得税费用 | 33,810,546.37 | 19,999,230.49 | 10,443,818.42 | 36,138,675.25 |
| 六、净利润 | 265,351,950.55 | 166,494,080.22 | 88,724,501.72 | 249,848,866.44 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 265,351,950.55 | 166,494,080.22 | 88,724,501.72 | 249,848,866.44 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 268,283,287.89 | 169,238,666.58 | 88,257,931.44 | 255,216,208.09 |
| 少数股东损益 | -2,931,337.34 | -2,744,586.36 | 466,570.28 | -5,367,341.65 |
| 扣除非经常损益后的净利润 | 212,675,316.25 | 141,471,405.86 | 70,827,987.91 | 193,089,411.89 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.61 | 0.39 | 0.2 | 0.59 |
| (二)稀释每股收益 | 0.61 | 0.39 | 0.2 | 0.58 |
| 八、其他综合收益 | -65,219.22 | - | - | - |
| 归属于母公司股东的其他综合收益 | -60,073.03 | - | - | - |
| 九、综合收益总额 | 265,286,731.33 | 166,494,080.22 | 88,724,501.72 | 249,848,866.44 |
| 归属于母公司股东的综合收益总额 | 268,223,214.86 | 169,238,666.58 | 88,257,931.44 | 255,216,208.09 |
| 归属于少数股东的综合收益总额 | -2,936,483.53 | -2,744,586.36 | 466,570.28 | -5,367,341.65 |
| 公告日期 | 2025-10-24 | 2025-08-29 | 2025-04-29 | 2025-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |